Effectiveness of Injectable Risperidone for Schizophrenia
Author Information
Author(s): Tim Lambert, José M Olivares, Joseph Peuskens, Cherilyn DeSouza, Chris M Kozma, Patrick Otten, Concetta Crivera, An Jacobs, Wayne Macfadden, Lian Mao, Stephen C Rodriguez, Riad Dirani, Kasem S Akhras
Primary Institution: University of Sydney
Hypothesis
The analysis aims to describe the effectiveness of injectable risperidone long-acting therapy (RLAT) for schizophrenia across different countries.
Conclusion
RLAT in patients with schizophrenia was associated with improvements in clinical and functional outcomes and decreased hospitalization rates across multiple countries.
Supporting Evidence
- Improvements were observed on clinical assessments across countries.
- Hospitalization rates decreased significantly in all countries after RLAT initiation.
- The study included data from 3,069 patients across the US, Spain, Australia, and Belgium.
Takeaway
This study found that a special injection for schizophrenia helps people feel better and go to the hospital less often.
Methodology
This was a pragmatic analysis of data from two prospective observational studies conducted in the US and other countries, assessing clinical improvement and hospitalization rates.
Potential Biases
Potential selection bias due to excluding patients with only a baseline visit.
Limitations
The study was not randomized, which limits causal inference, and relied on retrospective data for hospitalization rates.
Participant Demographics
Patients were aged 18 years or older with schizophrenia, with a mean age ranging from 38.8 to 42.4 years across countries.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI calculated using bootstrap resampling method.
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website